Search for: "D. O. B." Results 6141 - 6160 of 7,686
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Aug 2022, 11:42 am by Kevin LaCroix
All of these factors, individually or collectively, are certainly affecting businesses these days and could in fact lead to securities litigation or other D&O claims. [read post]
29 Jul 2021, 2:05 pm by Kevin LaCroix
It also seems that these developments will not help calm the current disrupted D&O insurance marketplace for SPACs and de-SPAC companies. [read post]
29 Mar 2013, 3:58 am by Lorene Park
A federal court in Texas ruled that seven African-American freight terminal employees who were subjected to racist graffiti, epithets, property damage, and the presence of nooses at work could proceed on their Title VII hostile work environment claims (Brooks v Yellow Transportation, Inc c/o The Frick Co, March 18, 2013, No. 3:06-CV-1566-D). [read post]
26 Jul 2019, 6:17 am
Posted by Cydney Posner, Cooley LLP, on Wednesday, July 24, 2019 Tags: Accounting, Commonsense Principles, Drag-along rights, Financial reporting, Institutional Investors, Long-Term value, R&D, Repurchases, Securities regulation, Short-termism The Importance of Climate Risks for Institutional Investors Posted by Philipp Krueger (University of Geneva), Zacharias Sautner (Frankfurt School of Finance & Management), and Laura T.… [read post]
10 Mar 2012, 10:26 am by Stefan Padfield
” Again, I quote Frankel from her post linked to above: “I should note that if the deal goes through as expected, Kinder Morgan will likely indemnify El Paso for any payments to shareholders; [El Paso CEO] Foshee is surely covered by D&O insurance, although he could meet resistance from his insurer if he's found to have breached his duty. [read post]
12 May 2017, 2:08 pm by Robert B. Lamm
  D&O bars Would repeal the SEC’s authority to bar persons from serving as directors or officers of publicly held companies   A long-standing weapon in the SEC’s enforcement arsenal It’s anybody’s guess whether the CHOICE Act will continue to rumble through Congress and the extent to which the above provisions will change – or whether additional provisions will be added. [read post]
2 Nov 2011, 2:00 am by Marie Louise
Prometheus: the patentee’s section 101 argument (Patently-O) US: CAFC Permits post-filing date unexpected results to support non-obviousness: Genetics Institute v. [read post]
19 Mar 2020, 9:05 pm by Alana Bevan
District Judge William B. [read post]
1 May 2011, 10:09 am by emagraken
[Emphasis added.] d)         Recently, in Catalyst Paper Corporation v. [read post]
16 Oct 2016, 5:28 pm by Gerald Maatman, Jr. and Alex W. Karasik
Case Background As we discussed in previous blog posts about this case here, here, and here, the charging party was a nurse for Vicksburg Healthcare, LLC d/b/a River Region Medical Center (“River Region”). [read post]
26 Nov 2014, 2:27 pm by Colin O'Keefe
Then there’s Dewey B Strategic from Jean O’Grady, Director of Research Services and Libraries at DLA Piper. [read post]
23 Nov 2016, 11:02 am by Kirsten Stefanik
“War has changed,” began LGen Dallaire (Ret’d), “therefore our tactics need to change. [read post]
19 Oct 2011, 3:30 am by Marie Louise
: Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon (IPKat) (The SPC Blog) Naprelan (Naproxen) – US: Lawsuit seeks to compel FDA compliance with PDUFA user fee waiver provisions: Stat-Trade v USFDA (FDA Law Blog) OxyContin(Oxycodone) – US: Purdue Pharma files patent infringement complaint against Ranbaxy in response to Para IV certification filing (Patent Docs) Plavix (Clopidogrel) – US: CAFC: Apotex wins on… [read post]